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Abstract
Background
There is growing evidence that Alzheimer disease (AD) is a pervasive metabolic disorder
with dysregulation in multiple biochemical pathways underlying its pathogenesis. Under-
standing how perturbations in metabolism are related to AD is critical to identifying novel tar-
gets for disease-modifying therapies. In this study, we test whether AD pathogenesis is
associated with dysregulation in brain transmethylation and polyamine pathways.
Methods and findings
We first performed targeted and quantitative metabolomics assays using capillary electro-
phoresis-mass spectrometry (CE-MS) on brain samples from three groups in the Baltimore
Longitudinal Study of Aging (BLSA) (AD: n = 17; Asymptomatic AD [ASY]: n = 13; Control
[CN]: n = 13) (overall 37.2% female; mean age at death 86.118 ± 9.842 years) in regions
both vulnerable and resistant to AD pathology. Using linear mixed-effects models within two
primary brain regions (inferior temporal gyrus [ITG] and middle frontal gyrus [MFG]), we
tested associations between brain tissue concentrations of 26 metabolites and the following
primary outcomes: group differences, Consortium to Establish a Registry for Alzheimer’s
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Disease (CERAD) (neuritic plaque burden), and Braak (neurofibrillary pathology) scores.
We found significant alterations in concentrations of metabolites in AD relative to CN sam-
ples, as well as associations with severity of both CERAD and Braak, mainly in the ITG.
These metabolites represented biochemical reactions in the (1) methionine cycle (choline:
lower in AD, p = 0.003; S-adenosyl methionine: higher in AD, p = 0.005); (2) transsulfuration
and glutathione synthesis (cysteine: higher in AD, p < 0.001; reduced glutathione [GSH]:
higher in AD, p < 0.001); (3) polyamine synthesis/catabolism (spermidine: higher in AD, p =
0.004); (4) urea cycle (N-acetyl glutamate: lower in AD, p < 0.001); (5) glutamate-aspartate
metabolism (N-acetyl aspartate: lower in AD, p = 0.002); and (6) neurotransmitter metabo-
lism (gamma-amino-butyric acid: lower in AD, p < 0.001). Utilizing three Gene Expression
Omnibus (GEO) datasets, we then examined mRNA expression levels of 71 genes encoding
enzymes regulating key reactions within these pathways in the entorhinal cortex (ERC; AD:
n = 25; CN: n = 52) and hippocampus (AD: n = 29; CN: n = 56). Complementing our metabo-
lomics results, our transcriptomics analyses also revealed significant alterations in gene
expression levels of key enzymatic regulators of biochemical reactions linked to transmethy-
lation and polyamine metabolism. Our study has limitations: our metabolomics assays mea-
sured only a small proportion of all metabolites participating in the pathways we examined.
Our study is also cross-sectional, limiting our ability to directly test how AD progression may
impact changes in metabolite concentrations or differential-gene expression. Additionally,
the relatively small number of brain tissue samples may have limited our power to detect
alterations in all pathway-specific metabolites and their genetic regulators.
Conclusions
In this study, we observed broad dysregulation of transmethylation and polyamine synthe-
sis/catabolism, including abnormalities in neurotransmitter signaling, urea cycle, aspartate-
glutamate metabolism, and glutathione synthesis. Our results implicate alterations in cellular
methylation potential and increased flux in the transmethylation pathways, increased
demand on antioxidant defense mechanisms, perturbations in intermediate metabolism in
the urea cycle and aspartate-glutamate pathways disrupting mitochondrial bioenergetics,
increased polyamine biosynthesis and breakdown, as well as abnormalities in neurotrans-
mitter metabolism that are related to AD.
Author summary
Why was this study done?
• A growing body of evidence suggests that Alzheimer disease (AD) may be associated
with dysregulation of multiple metabolic pathways, and identifying novel molecular tar-
gets underlying AD pathogenesis is essential for developing effective AD treatments.
• Past studies have shown that abnormalities in choline-related biochemical pathways
may be associated with AD pathogenesis, specifically the transmethylation, polyamine
synthesis/catabolism and related pathways.
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• Our study tested the hypothesis that dysregulation of choline-related biochemical path-
ways in the brain is associated with AD pathogenesis; we examined metabolites within
biochemical reactions linked to transmethylation and polyamine synthesis/catabolism.
What did the researchers do and find?
• We performed quantitative and targeted metabolomics on brain tissue samples (AD:
n = 17; Asymptomatic AD [ASY]: n = 13; Control [CN]: n = 13) and transcriptomics
from Gene Expression Omnibus data (entorhinal cortex [AD: n = 25; CN: n = 52] and
hippocampus [AD: n = 29; CN: n = 56]) to identify aberrations across 6 biochemical
reactions linked to the transmethylation and polyamine pathways: methionine cycle,
transsulfuration and glutathione synthesis, polyamine synthesis and catabolism, urea
cycle, glutamate-aspartate metabolism, and neurotransmitter metabolism.
• We found significant metabolite alterations associated with AD mainly in the inferior
temporal gyrus (ITG) across all pathways tested, as well as associations between metabo-
lite concentrations and severity of AD pathology.
• Complementing our metabolomics results, our transcriptomics analyses also revealed
significant alterations in gene expression of key enzymatic regulators of biochemical
reactions linked to transmethylation and polyamine metabolism.
What do these findings mean?
• Our results implicate alterations in cellular methylation potential and increased flux in
the transmethylation pathways, increased demand on antioxidant defense mechanisms,
perturbations in intermediate metabolism in the urea cycle and aspartate-glutamate
pathways disrupting mitochondrial bioenergetics, increased polyamine biosynthesis
and breakdown, as well as abnormalities in neurotransmitter metabolism that are
related to severity of AD pathology and the expression of clinical symptoms.
• This study adds to a comprehensive understanding of the metabolic basis of AD patho-
genesis and provides insights into novel targets for disease-modifying therapies.
• The cross-sectional nature of the study limits our ability to directly test how AD pro-
gression may impact changes in metabolite concentrations or differential-gene
expression.
Introduction
A growing body of evidence suggests that Alzheimer disease (AD) is a pervasive metabolic dis-
order with dysregulation of multiple biochemical pathways that may be associated with both
severity of AD pathology in the brain and eventual expression of disease symptoms [1–4]. An
enhanced understanding of abnormal metabolism in AD is likely to provide insights into
novel targets for disease-modifying therapies. While the predominant approach towards AD
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treatments has targeted amyloid-beta (Aβ), the repeated failures of clinical trials of anti-amy-
loid therapies highlights the pressing need to identify novel molecular targets that may under-
lie AD pathogenesis [5–7].
In recent studies, we have used both targeted and untargeted metabolomics methods in
both brain and blood to study the role of abnormal metabolism in AD pathogenesis [8,9].
These studies have revealed dysregulation in brain glycolysis as well as perturbations in meta-
bolic pathways derived from acetyl–coenzyme A (CoA), produced by oxidation of the end
product of glycolysis—pyruvate. These pathways include fatty acid and phospholipid metabo-
lism [9,10]. Broadly, our prior results suggest that abnormalities in glycolysis in AD may
impact the supply of cytosolic acetyl-CoA, which can lead to perturbations in other interme-
diate metabolic pathways. In addition to synthesis of fatty acids and their subsequent incor-
poration into phospholipids, acetyl-CoA combines with choline in cholinergic neurons to
form the neurotransmitter acetylcholine. Acetylcholine plays a critical role in learning and
memory, and abnormalities in cholinergic neurotransmission are thought to underlie cogni-
tive impairment in AD [11]. Furthermore, acetylcholinesterase inhibitors constitute the
major class of drugs that are currently approved symptomatic treatments for AD [12]. Cho-
line is also a key participant in one-carbon metabolism (OCM) through its oxidation product
betaine and constitutes the head group of phosphatidylcholines in cell membranes. Abnor-
malities in both OCM and phosphatidylcholine metabolism have previously been implicated
in AD [13,14].
In this study, we therefore tested the hypothesis that dysregulation of choline-related bio-
chemical pathways in the brain are associated with AD pathogenesis. We a priori selected the
transmethylation pathway, the primary source of one-carbon units, and the closely related
polyamine synthesis/catabolism pathway, both of which have been implicated in cell survival
and signaling cascades relevant to neurodegeneration [15–19]. We examined metabolites
within biochemical reactions linked to transmethylation and polyamine synthesis/catabolism
within the following six categories: methionine cycle, transsulfuration and glutathione synthe-
sis, polyamine synthesis/catabolism, urea cycle, glutamate-aspartate metabolism, and neuro-
transmitter metabolism. We analyzed available concentrations of metabolites within these
categories derived from targeted metabolomics assays of brain tissue samples from the autopsy
cohort of the Baltimore Longitudinal Study of Aging (BLSA). These assays were performed
using capillary electrophoresis-mass spectrometry (CE-MS), an approach distinct from our
prior metabolomics studies that examined abnormalities in brain glycolysis [8] and fatty acid
[10] and glycerophospholipid [9] metabolism in AD using flow injection analysis-mass spec-
trometry (FIA-MS/MS) and liquid chromatography-tandem mass spectrometry (LC-MS/MS).
We then analyzed publicly available transcriptomic datasets to test whether gene expression of
genetic regulators of these pathways were altered in brain regions where accumulation of AD
pathology is known to trigger the onset of cognitive impairment.
Methods
This study is reported as per the STROBE guideline (S1 Table).
Participants
Quantitative brain metabolomics. The National Institute on Aging’s (NIA’s) BLSA is
one of the longest running scientific studies of human aging in the United States. [20]. This
observational study began in 1958 and includes longitudinal clinical, radiological, and
Dysregulation of transmethylation and polyamine pathways in AD
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laboratory evaluations on community-dwelling volunteer participants. Participants are
assessed every two years, and starting in 2003, participants older than 80 years are assessed
annually.
Our sample consisted of a subset of participants from the autopsy program of the BLSA
[21]. The autopsy subsample is not significantly different from the overall BLSA cohort in
terms of rates of dementia and clinical stroke [22]. Postmortem brains were examined by an
expert neuropathologist to assess AD pathology. As described previously [23], the Consortium
to Establish a Registry for Alzheimer’s Disease (CERAD) and Braak criteria were used to assess
severity of AD pathology based on neuritic plaques [24] and neurofibrillary tangles [25],
respectively. Autopsy participants were classified within three groups based on the following
criteria: AD participants (n = 17) had a clinical diagnosis of either AD or mild cognitive
impairment (MCI) due to AD within 1 year of death and a CERAD pathology score of>1 (i.e.,
CERAD B or C); control (CN) participants (n = 13) had normal cognition within 1 year of
death and a CERAD pathology score�1 (i.e., CERAD 0 or A); and asymptomatic AD (ASY)
participants (n = 13) had normal cognition within 1 year of death and a CERAD pathology
score >1 (i.e., CERAD B or C). The ASY group has been described in detail previously [26]
and represents individuals who at autopsy had brain pathology characteristic of AD but did
not exhibit clinical symptoms of AD (i.e., cognitive impairment) during life as assessed by lon-
gitudinal neuropsychological assessments.
Written informed consent was obtained at each visit for all BLSA participants. The BLSA
study protocol has ongoing approval from the Institutional Review Board of the National Insti-
tute of Environmental Health Science, National Institutes of Health (“Early Markers of Alzhei-
mer’s Disease [BLSA],” Institutional Review Board number 2009–074).
Brain gene expression. Our gene expression data were downloaded from three publicly
available microarray gene expression datasets (Gene Expression Omnibus [GEO]: GSE48350,
GSE5281, and GSE84422). The datasets contained gene expression data on AD and CN brain
samples representing 23 distinct brain regions, acquired on the Affymetrix U133 Plus2 array
platform. As prior studies have suggested that the entorhinal cortex (ERC) and the hippocam-
pus are primary regions of early AD pathology accumulation [27] that trigger cognitive
impairment [28,29], we performed a focused analysis of gene expression data from the ERC
(AD: n = 25 and CN: n = 52) and the hippocampus (AD: n = 29 and CN: n = 56).
Brain tissue
Tissue samples from participants in three groups (AD: n = 17; ASY: n = 13; CN: n = 13) were
extracted from the cortical surface of autopsied brains using a sterile 4-mm-diameter tissue
punch from three regions: inferior temporal gyrus (ITG), middle frontal gyrus (MFG), and
cerebellum (CB). The ITG and the MFG represent our primary regions of interest and repre-
sent specific a priori hypotheses regarding the relationship between metabolite levels and dis-
tinct features of AD pathology. The ITG was chosen as a region of early tau accumulation and
neurofibrillary pathology, while the MFG was chosen as a site of Aβ deposition and neuritic
plaque pathology [30,31]. We hypothesized that both the ITG and MFG would be sites of met-
abolic pathway dysregulation associated with specific features of AD pathology. On the other
hand, the CB was chosen primarily as a control, as the CB represents a brain region that is rela-
tively unaffected by AD pathology [32]. In this ancillary analysis, we hypothesized that the
metabolic pathways we assessed would not be altered and we would not observe significant dif-
ferences in metabolite concentration across groups (i.e., AD, ASY, CN). Brain tissue samples
from the ERC and hippocampus were not available for metabolomic profiling. All tissue sam-
ples were stored at −80 ˚C until metabolomic assays.
Dysregulation of transmethylation and polyamine pathways in AD
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Metabolomic profiling
Sample preparation. Quantitative and targeted metabolomics assays were performed on
brain tissue samples by capillary electrophoresis time-of-flight mass spectrometry
(CE-TOFMS) with the operator blinded to diagnoses. Metabolite measurements were carried
out at Human Metabolome Technologies, Tsuruoka, Japan. Approximately 50 mg of frozen
brain tissue was plunged into 1.5 mL of 50% acetonitrile/Milli-Q water at 0 ˚C containing
20 μM and 5 μM of internal standard for the cation (methionine sulfone) and anion (10-cam-
phorsulfonic acid) modes, respectively, as described previously [33,34]. The tissue was homog-
enized thrice at 1,500 rpm for 120 seconds using a tissue homogenizer (Microsmash MS100R,
Tomy Digital Biology, Tokyo, Japan). The homogenate was centrifuged at 2,300g and 4 ˚C for
5 minutes. Subsequently, 800 μL of upper aqueous layer was transferred to a 5-kDa-cutoff filter
(Human Metabolome Technologies, Tsuruoka, Japan) to remove proteins. The filtrate was
dried using a centrifugal concentrator (Labconco Corporation, Kansas City, MO) and recon-
stituted with 50 μL of Milli-Q water for CE-MS analysis.
CE-TOFMS. CE-TOFMS was carried out using an Agilent CE Capillary Electrophoresis
System equipped with an Agilent 6210 Time of Flight mass spectrometer, Agilent 1100 iso-
cratic HPLC pump, Agilent G1603A CE-MS adapter kit, and Agilent G1607A CE-ESI-MS
sprayer kit (Agilent Technologies, Waldbronn, Germany). The systems were controlled by
Agilent G2201AA ChemStation software version B.03.01 for CE (Agilent Technologies, Wald-
bronn, Germany). The sample was injected at a pressure of 50 mbar for 10 seconds (approxi-
mately 10 nL) in cation analysis and 25 seconds (approximately 25 nL) in anion analysis. The
spectrometer was scanned from mass-to-charge ratio (m/z) 50 to 1,000. Other conditions were
as described previously by Soga and colleagues [35–37].
Peaks were extracted using automatic integration software ver. 2.13.0.8 (MasterHands,
Keio University, Tsuruoka, Japan) [34] and were aligned according to m/z and migration time
(MT). The relative area value was calculated by dividing the acquired peak area value by that of
the internal standard and the sample volume [34, 38]. After peak picking, the MT drifts of all
electropherograms in each sample were corrected based on those of the internal standards
containing methionine sulfone and 10-camphorsulfonic acid by fitting quadratic functions.
The peak matrix was matched against the annotation table of the in-house metabolomic library
(Human Metabolome Technologies) described previously on the basis of their m/z and MTs
[38]. The tolerance range for the peak annotation was configured at ±0.2 minutes for MT and
±10 ppm for m/z.
HMT’s in-house metabolite library contains 1,363 compounds, as described recently by
Sasaki and colleagues [39]. A full listing of available compounds in the library is accessible
through their recent publication at https://pubs.acs.org/doi/abs/10.1021/acs.analchem.
8b02994.
CE-TOFMS analysis using the current system enables measurement of the concentrations
of 130 major metabolites in each sample on the basis of their peak areas. Six-point calibration
curves were previously derived using standard compounds for each metabolite reported herein
to evaluate the linearity and detection limits for each analyte. In assays performed in the cur-
rent study, we calculate the concentration of metabolites in singlicate using 1-point calibration
of each standard compound in the linear range at 100 μM.
These metabolites represent glycolysis, pentose phosphate pathway, TCA cycle, neuro-sig-
naling, and the urea cycle, as well as polyamine, creatine, purine, glutathione, nicotinamide,
choline, and amino acid metabolism. Quantification is performed using the (M+H)+ or
(M-H)− parent ion peak area for each metabolite compared to the same parent peak in the
standard solution. Concentration is only reported if the measured area is above a signal-to-
Dysregulation of transmethylation and polyamine pathways in AD
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noise ratio (S/N) of 5 and the peak area is within the linear range of the standard curve [39].
Coefficients of variation (CVs) for repeat technical samples using this methodology were less
than 10%, as reported previously by Soga and colleagues [40]. S2 Table includes a list of all 27
metabolites in the transmethylation and polyamine pathways that were studied in this report,
including their class, ion type, m/z, MT, S/N, and limit of detection data.
Of the 130 metabolites that could be quantified in brain tissue samples, we a priori identi-
fied 27 metabolites that represented reactions within the transmethylation and polyamine
pathways, which were the main focus of our study. In order to enhance ease of interpretation
of our results, we grouped these metabolites into six categories based on the primary biochemi-
cal reactions in which they participate. These categories and their constituent metabolites (26
metabolites after exclusion of spermine, based on criteria described in Statistical Analyses)
include the following:
1. Methionine cycle: betaine, choline, creatine, methionine (Met), methionine sulfoxide, S-
adenosylmethionine (SAM), S-adenosylhomocysteine (SAH), and symmetric dimethylargi-
nine (SDMA).
2. Transsulfuration and glutathione synthesis: reduced glutathione (GSH), oxidized glutathi-
one disulfide (GSSG), cysteine (Cys), and cystathionine.
3. Polyamine synthesis and catabolism: putrescine and spermidine.
4. Urea cycle: arginine, argininosuccinic acid, citrulline, N-acetylglutamate (NAG), ornithine,
and urea.
5. Glutamate-aspartate metabolism: alanine, aspartate, glutamine (Gln), and glutamate (Glu).
6. Neurotransmitter metabolism: Gamma-amino-butyric acid (GABA) and N-acetylaspartate
(NAA).
Gene expression
Because accumulation of pathology in the ERC and hippocampus is believed to trigger the
onset of AD symptoms [27–29], we were also interested in examining whether differential
expression of genes regulating reactions within the six biochemical categories described above
could be detected in these regions.
We generated an a priori list of genes known to encode enzymes regulating individual reac-
tions within the same six biochemical categories described above for the classification of
assayed metabolites.
In order to confirm that regional gene expression in the ERC and hippocampus represented
measures relevant to those in the ITG and MFG where our metabolomics assays were per-
formed, we also examined correlations between gene expression in the ERC and hippocampus
with gene expression in the ITG and MFG.
Statistical analyses
The overall study design was developed conceptually prior to the start of data analyses in July
2018 and is similar to the design implemented in our prior papers [9,10]. The study did not
have a prespecified analysis plan. Based on reviewer recommendations, we updated our ana-
lytic approach from independent Kruskal-Wallis tests to cluster-based generalized linear
mixed models to more appropriately account for correlations between metabolites within our
a priori–defined metabolite categories, as well as to better adjust for multiple comparisons.
Dysregulation of transmethylation and polyamine pathways in AD
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As in our previous metabolomics analyses [9], metabolites with greater than 30% of values
missing were dropped from all analyses. From the a priori–defined 27 principal metabolites in
the transmethylation and polyamine pathways, 1 metabolite (spermine) was dropped due to
missingness >30%. For the remaining metabolites (i.e., 26 in total), values indicated as less
than the limit of detection were imputed as the lowest detectable value divided by 2 (1.15% of
metabolites imputed on average).
R-Studio 1.1.453 and Stata 16.0 were used for analyses. Statistical significance was deter-
mined using an alpha of 0.05. While we present our findings as exploratory, multiple compari-
sons controlling for Benjamini-Hochberg false discovery rate (FDR = 0.05) [41] and
Bonferroni family-wise error rate (FWER = 0.05) were conducted in response to reviewers
suggestions; Bonferroni techniques are known to be markedly conservative and can be inap-
propriate when control regions are included [42]. Both multiple comparison methods cor-
rected for 52 comparisons (26 metabolites × 2 primary brain regions of interest [ITG and
MFG]) that were a priori specified based on their vulnerability to distinct AD pathologies. Dif-
ferences across the three groups (AD, ASY, and CN) in sex, APOE ε4 carrier status (Fisher-
exact test), age, and postmortem interval (PMI) (Kruskal-Wallis test) were examined.
The main analysis of interest was to assess differences in metabolite levels across groups.
We used linear mixed-effects models on each of the a priori–defined metabolite categories
(i.e., clusters) within each of the two primary brain regions (ITG and MFG) as well as the sec-
ondary control region (CB), with log2-transformed concentrations as the dependent variable,
group as the fixed effect, unstructured within-subject residual correlations, and Huber-White
robust variance estimates. Using the same analytic approach, we also examined brain tissue
metabolite associations with Braak and CERAD pathology scores for the primary brain regions
only (i.e., ITG and MFG) based on reviewer recommendations to look at associations with
pathology only for brain regions with significant group differences. Sensitivity analyses using
generalized estimating equation (GEE) clustered analyses and nonparametric Spearman corre-
lations with independent Kruskal-Wallis tests gave similar results.
For gene expression data, we first normalized the samples using Robust Multi-array Average
(RMA) [43] with the Brainarray ENTREZG (version 22) custom CDF [44]. We used the GEO
datasets GSE48350, GSE5281, and GSE8442, and we used the GEO dataset name as the batch
covariate for all further statistical analyses. We then tested for differences in sex, age, and batch
between AD and CN samples using the one-way ANOVA test. The R package limma [45] was
used to test each gene univariately for differences between AD and CN samples, controlling for
the effects of sex, age, and batch and adjusting for multiple comparisons using the FDR (set at
p = 0.05) [41] accounting for all 20,414 genes on the Affymetrix U133 Plus 2.0 array used in the
GEO datasets. We summarized results of sex, age, and batch-corrected fold changes indicating
whether genes were differentially expressed in AD versus CN samples and visualized significant
(either in the hippocampus and/or ERC) results using a heatmap. Red and green represent
increased and reduced expression, respectively, of the gene in AD versus CN samples (i.e., red
indicates that the gene had increased expression in AD samples compared to CN samples, and
green indicates that the gene has reduced expression in AD samples compared to CN samples).
Analytic code used in statistical analyses are available upon request to the corresponding
author.
Results
Participants
The demographic characteristics of BLSA participants in the autopsy cohort sample are sum-
marized in Table 1. As reported previously [9], the three groups did not differ significantly in
Dysregulation of transmethylation and polyamine pathways in AD
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age at death, sex, apolipoprotein E (APOE ε4) carrier status, or PMI. Demographic characteris-
tics of participants whose gene expression data were available in the three GEO datasets are
included in Table 2. In the GEO data, AD participants were significantly older than CN partic-
ipants (p< 0.05). BLSA participants and GEO participants did not differ by sex; BLSA partici-
pants were significantly older than GEO participants (p< 0.05).
Brain tissue metabolite concentrations and their associations with AD
S3 Table indicates regional brain tissue concentrations (picomoles per milligram of brain tis-
sue) of assayed metabolites by group.
Below, for our main analysis, we indicate significant metabolite concentration differences
across groups by category (Fig 1) and include forest plots visualizing the direction of change
and effect size. We additionally indicate associations between metabolite concentration and
neuritic plaque burden (i.e., CERAD scores) (Fig 2) and neurofibrillary pathology (i.e., Braak
scores) (Fig 3). Metabolites that are significantly altered after FDR correction are colored in
green (indicating a lower metabolite concentration in AD or negative association with AD
pathology) or red (indicating a higher metabolite concentration in AD or positive association
with AD pathology) in Figs 1–3, and metabolites that remain statistically significant after Bon-
ferroni correction are additionally indicated in bold. We visualize results specifically for the
main results—ITG group differences—in pathway-specific figures. As suggested by the
Table 1. Demographic characteristics of the BLSA autopsy sample.
Characteristics Total CN ASY AD p-value
n 43 13 13 17 -
Female (%) 37.2 23.1 38.5 47.1 0.401
Age (mean, SD) 86.118 (9.842) 82.427 (11.510) 88.218 (8.041) 87.411 (9.468) 0.380
APOE ε4 allele (%) 23.3 23.1 23.1 23.5 >0.999
PMI (hours) (mean, SD) 15.179 (6.760) 16.818 (6.0467) 15.042 (8.677) 14.156 (5.750) 0.715
Differences in sex and APOE ε4 allele were tested with the Fisher test, and differences in age and PMI were tested with the Kruskal-Wallis test.
Abbreviations: AD, Alzheimer disease; APOE ε4, apolipoprotein E; ASY, asymptomatic AD; BLSA, Baltimore Longitudinal Study of Aging; CN, Control; PMI,
postmortem interval
https://doi.org/10.1371/journal.pmed.1003012.t001
Table 2. Demographics of individuals from GEO data.
Brain Region and Characteristics AD CN Total p-value
ERC 25 52 77
Female (%) 56.0 40.4 45.5 0.228
Age (mean, SD) 86.12 (5.718) 62.288 (24.526) 70.026 (23.241) <0.001�
Hippocampus 29 56 85
Female (%) 48.3 41.1 43.5 0.645
Age (mean, SD) 81.241 (7.945) 66.464 (23.766) 71.506 (20.989) 0.010�
Total 54 108 162
�Indicates p-value <0.05 for global group differences across demographic characteristics.
Differences in sex were tested with the Fisher test, and differences in age were tested with the Kruskal-Wallis test.
Abbreviations: AD, Alzheimer disease; CN, control; ERC, entorhinal cortex; GEO, Gene Expression Omnibus
https://doi.org/10.1371/journal.pmed.1003012.t002
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reviewers, we include both FDR- and Bonferroni-corrected p-values in all tables. In results
described below in the text as well as pathway-specific figures, we report FDR-corrected p-val-
ues and indicate whether metabolites were additionally also significant after Bonferroni cor-
rection with an asterisk. We report ancillary analyses within the CB in S4 Table.
As reported previously, the three groups (AD, ASY, and CN) differed significantly in the
severity of neuritic plaque and neurofibrillary pathology, as measured by CERAD and Braak
scores, respectively (p< 0.0001), with the AD group showing the highest, ASY group showing
intermediate, and CN group showing the lowest levels of pathology [8].
Methionine cycle (Fig 4). We observed a lower concentration of choline (ITG: p = 0.003�;
MFG: p = 0.002�) in AD, as well as associations between a lower concentration of choline and
greater neuritic plaque burden (ITG: p = 0.003�; MFG: p = 0.003�) and greater neurofibrillary
pathology (ITG: p< 0.001�; MFG: p< 0.001�). We observed a higher concentration of SAM
(ITG: p = 0.005; MFG: p = 0.016) in AD as well as associations between higher concentrations
of SAM and greater neuritic plaque burden (ITG: p = 0.006; MFG: p = 0.020). We also
observed a higher concentration of SAH (MFG: p = 0.031) in AD.
Fig 1. Group differences in category-specific metabolite concentrations. Metabolites in green or red (not bold) were significant
after FDR correction for 52 comparisons; metabolites in green or red (bold) were also significant after Bonferroni correction for 52
comparisons. Differences in metabolite concentration across groups were tested using linear mixed-effects models for each
metabolite category. AD, Alzheimer disease; Bon, Bonferroni; FDR, false discovery rate; Glutamate Aspartate Metab, glutamate-
aspartate metabolism; ITG, inferior temporal gyrus; MFG, medial temporal gyrus; Poly Synth & Cat, polyamine synthesis and
catabolism; Transsulf and Glutath, transsulfuration and glutathione synthesis.
https://doi.org/10.1371/journal.pmed.1003012.g001
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Transsulfuration and glutathione synthesis (Fig 5). We observed a higher concentration
of cysteine (ITG: p< 0.001�; MFG: p< 0.001�) in AD, as well as associations between higher
concentrations of cysteine and greater neuritic plaque burden (ITG: p = 0.002�; MFG:
p< 0.001�) and greater neurofibrillary pathology (ITG: p< 0.001�; MFG: p = 0.008). We
observed a higher concentration of GSH (ITG: p< 0.001�; MFG: p< 0.001�) in AD, as well as
associations between higher concentrations of GSH and greater neuritic plaque burden (ITG:
p = 0.003�; MFG: p = 0.002�) and greater neurofibrillary pathology (ITG: p< 0.001�; MFG:
p = 0.010).
Polyamine synthesis and catabolism (Fig 6). We observed a higher concentration of
spermidine (ITG: p = 0.004) in AD, as well as associations between higher concentration of
spermidine and greater neuritic plaque burden (ITG: p = 0.002�; MFG: p = 0.013) and greater
neurofibrillary pathology (ITG: p = 0.003�).
Urea cycle (Fig 7). We observed a lower concentration of NAG (ITG: p< 0.001�; MFG:
p = 0.031) in AD, as well as associations between lower concentrations of NAG and greater
neuritic plaque burden (ITG: p = 0.004�) and greater neurofibrillary pathology (ITG:
p = 0.001�; MFG: p = 0.005�).
Glutamate-aspartate metabolism (Fig 8). We observed a lower concentration of NAA
(ITG: p = 0.002�) in AD, as well as associations between lower concentrations of NAA and
greater neuritic plaque burden (ITG: p = 0.003�) and greater neurofibrillary pathology (ITG:
p = 0.005).
Fig 2. Associations between category-specific metabolites and neuritic plaque burden (CERAD). Metabolites in
green or red (not bold) were significant after FDR correction for 52 comparisons; metabolites in green or red (bold)
were also significant after Bonferroni correction for 52 comparisons. Associations with pathology were tested using
linear mixed-effects models for each metabolite category. Bon, Bonferroni; CERAD, Consortium to Establish a
Registry for Alzheimer’s Disease; FDR, false discovery rate; Glutamate Aspartate Metab, glutamate-aspartate
metabolism; ITG, inferior temporal gyrus; MFG, medial temporal gyrus; Poly Synth & Cat, polyamine synthesis and
catabolism; Transsulf and Glutath, transsulfuration and glutathione synthesis.
https://doi.org/10.1371/journal.pmed.1003012.g002
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Neurotransmitter metabolism (Fig 9). We observed a lower concentration of GABA
(ITG: p< 0.001�; MFG: p = 0.010) in AD, as well as associations between lower concentrations
of GABA and greater neuritic plaque burden (ITG: p = 0.003�; MFG: p = 0.028) and greater
neurofibrillary pathology (ITG: p = 0.014; MFG: p = 0.007).
For ancillary analyses in the secondary, control brain region (CB), we observed no signifi-
cant metabolite differences across groups.
Gene expression
We first tested whether regional gene expression changes in the 71 genes we examined in the
inferior temporal and middle frontal cortices were significantly correlated with those in the
hippocampus and ERC. We observed that regional gene expression in the ITG was indeed sig-
nificantly correlated with that in the hippocampus (ρ = 0.455, p = 5.9 × 10−5) and ERC (ρ =
0.260, p = 0.0276), as was the regional gene expression in the MFG (hippocampus: ρ = 0.512,
p = 4.19 × 10−6; ERC: ρ = 0.344, p = 0.0031).
We observed altered levels of gene expression between AD and CN ERC/hippocampus
within 33 genes (FDR-corrected p-value <0.05) across the six categories representing bio-
chemical reactions related to the transmethylation and polyamine pathways. These differences
Fig 3. Associations between category-specific metabolites and neurofibrillary pathology (Braak). Metabolites in green or red
(not bold) were significant after FDR correction for 52 comparisons; metabolites in green or red (bold) were also significant after
Bonferroni correction for 52 comparisons. Associations with pathology were tested using linear mixed-effects models for each
metabolite category. Bon, Bonferroni; CERAD, Consortium to Establish a Registry for Alzheimer’s Disease; FDR, false discovery
rate; Glutamate Aspartate Metab, glutamate-aspartate metabolism; ITG, inferior temporal gyrus; MFG, medial temporal gyrus;
Poly Synth & Cat, polyamine synthesis and catabolism; Transsulf and Glutath, transsulfuration and glutathione synthesis.
https://doi.org/10.1371/journal.pmed.1003012.g003
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in gene expression between AD and CN samples were statistically significant after correcting
for multiple comparisons using FDR (all results included in Table 3). We present significant
results (FDR-corrected p-value <0.05) in the heatmap (Fig 10) and additionally visualize sig-
nificant associations (FDR-corrected p-value <0.05) using arrows (with red indicating
increased expression in AD and green indicating decreased expression in AD) in each cate-
gory-specific figure (Figs 4–9). S4 Table lists all the genes whose expression levels differed
between AD and CN samples in the ERC/hippocampus together with their known biochemi-
cal roles and clinical significance.
Discussion
In this study, we extended our prior work demonstrating abnormal glycolysis [8] and fatty
acid [10] and phospholipid metabolism [9] in AD. We examined whether dysregulation in the
transmethylation pathway, the primary metabolic source of one-carbon units, and the closely
related polyamine synthesis/catabolism pathway were associated with AD pathogenesis. Our
findings provide evidence for broad dysregulation of transmethylation and polyamine synthe-
sis/catabolism, including abnormalities in neurotransmitter signaling, urea cycle, aspartate-
glutamate metabolism, and glutathione synthesis.
Methionine cycle (Fig 4)
We observed lower choline concentrations across all three brain regions in AD, as well as asso-
ciations with more severe amyloid pathology and neurofibrillary pathology. To the best of our
knowledge, this is the first study to measure absolute concentrations of free choline in AD
Fig 4. Methionine cycle. Differential brain concentrations of metabolites and differential gene expression of enzymatic regulators
are observed in the methionine cycle in AD. Lower concentration of choline and higher concentration of SAM are observed in
AD in the ITG. CHDH, BHMT2, SHMT1, and MAT1A genes have increased expression and MTR, AHCY, and MTHFD1 genes
have reduced expression in the hippocampus/ERC in AD compared to CN. Sample size: AD = 17, ASY = 13, CN = 13; p-values
indicate significance after FDR correction for multiple comparisons. Genes in light gray indicate expression data were not
available. An asterisk (�) indicates metabolite was also significant after Bonferroni correction. AD, Alzheimer disease; AHCY,
adenosylhomocysteinase; ASY, asymptomatic AD; BHMT2, betaine-homocysteine s-methyltransferase 2; CHDH, choline
dehydrogenase; CN, Control; ERC, entorhinal cortex; FDR, false discovery rate; ITG, inferior temporal gyrus; MAT1A, methionine
adenosyltransferase 1A; MTHFD1, methylenetetrahydrofolate dehydrogenase, cyclohydrolase, and formyltetrahydrofolate
synthetase 1; MTHFR, methylenetetrahydrofolate reductase; MTR, 5-methyltetrahydrofolate-homocysteine methyltransferase; SAH,
S-adenosyl homocysteine; SAM, S-adenosyl methionine; SHMT1, serine hydroxymethyltransferase 1.
https://doi.org/10.1371/journal.pmed.1003012.g004
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Fig 5. Transsulfuration and glutathione synthesis. Higher concentrations of cysteine and GSH are observed in AD in the ITG.
Differential gene expression of enzymatic regulators of transsulfuration and glutathione synthesis are observed in the hippocampus/
ERC in AD relative to controls. CTH and GSS genes have reduced expression in the hippocampus/ERC in AD compared to CN.
Sample size: AD = 17, ASY = 13, CN = 13; p-values indicate significance after FDR correction for multiple comparisons. An asterisk
(�) indicates metabolite was also significant after Bonferroni correction. AD, Alzheimer disease; ASY, asymptomatic AD; CBS,
cystathione β-synthase; CN, Control; CTH, cystathionase; ERC, entorhinal cortex; FDR, false discovery rate; GCLC, γ-glutamyl
cysteine ligase; GCLM, glutamate-cysteine ligase modifier subunit; GSH, reduced glutathione; GSS, GSH synthetase; ITG, inferior
temporal gyrus.
https://doi.org/10.1371/journal.pmed.1003012.g005
Fig 6. Polyamine synthesis and catabolism. A higher concentration of spermidine is observed in AD in the ITG. The
polyamine catabolic genes SAT1 and SMOX have increased expression, and the polyamine synthesis genes SRM and
ODC1 have reduced expression in the hippocampus/ERC in AD compared to CN. Sample size: AD = 17, ASY = 13,
CN = 13; p-values indicate significance after FDR correction for multiple comparisons. AD, Alzheimer disease; ASY,
asymptomatic AD; CN, Control; ERC, entorhinal cortex; FDR, false discovery rate; ITG, inferior temporal gyrus;
ODC1, ornithine decarboxylase 1; PAOX, peroxisomal N(1)-acetyl-spermine/spermidine oxidase; SAM, S-adenosyl
methionine; SAMDC/AMD1, S-adenosylmethionine decarboxylase proenzyme/adenosylmethionine decarboxylase 1;
SAT1, spermidine/spermine N1-acetyltransferase 1; SMOX, spermine oxidase; SMS, spermine synthase; SRM,
spermidine synthase.
https://doi.org/10.1371/journal.pmed.1003012.g006
Dysregulation of transmethylation and polyamine pathways in AD
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003012 January 24, 2020 14 / 31
Fig 7. Urea cycle. A lower concentration of NAG is observed in AD in the ITG. The genes ARG2, ASL, ASS1, OAT,
and ODC1 have reduced expression in the hippocampus/ERC in AD compared to CN. Sample size: AD = 17,
ASY = 13, CN = 13; p-values indicate significance after FDR correction for multiple comparisons. An asterisk (�)
indicates metabolite was also significant after Bonferroni correction. AD, Alzheimer disease; ARG1, arginase 1; ARG2,
arginase 2; ASL, argininosuccinate lyase; ASS, argininosuccinate synthase; ASY, asymptomatic AD; CN, Control;
CPS1, carbamoyl phosphate synthetase I; ERC, entorhinal cortex; FDR, false discovery rate; ITG, inferior temporal
gyrus; NAGS, N-acetylglutamate synthase; OAT, ornithine aminotransferase; ODC1, ornithine decarboxylase 1; OTC,
ornithine transcarbamylase; NAG, N-acetyl glutamate.
https://doi.org/10.1371/journal.pmed.1003012.g007
Fig 8. Glutamate-aspartate metabolism. A lower concentration of NAA is observed in AD in the ITG. The genes FH,
MDH1, MDH2, GLS2, and GOT2 have reduced expression in the hippocampus/ERC in AD compared to CN. Sample
size: AD = 17, ASY = 13, CN = 13; p-values indicate significance after FDR correction for multiple comparisons. Genes
in light gray indicate expression data were not available. An asterisk (�) indicates metabolite was also significant after
Bonferroni correction. Genes in light gray indicate expression data were not available. AD, Alzheimer disease; ASY,
asymptomatic AD; CN, Control; CoA, coenzyme A; ERC, entorhinal cortex; FDR, false discovery rate; FH, fumarase;
GLS2, glutaminase 2; GOT2, aspartate aminotransferase; ITG, inferior temporal gyrus; MDH1, malate dehydrogenase
1; MDH2, malate dehydrogenase 2; NAA, N-acetyl aspartate; NAT8L, N-acetyltransferase 8 like; PDH, pyruvate
dehydrogenase complex; SDH, succinate dehydrogenase.
https://doi.org/10.1371/journal.pmed.1003012.g008
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brain tissue samples and relate lower levels to greater severity of AD pathology. Using an
untargeted metabolomics approach, Paglia and colleagues reported increased levels of choline
in AD in the frontal cortex [46]. Methodological differences (quantitative targeted versus
untargeted metabolomics) may account for this inconsistent finding [46]. Most previous stud-
ies examining brain choline concentrations in AD have used proton magnetic resonance spec-
troscopy (1H-MRS); that detects the choline compounds, glycerophosphocholine, and
phosphocholine. These studies, as well as those measuring ratios of choline to creatine, have
been largely inconsistent [47–51]. Our current findings are significant as they suggest that
decreased brain choline concentrations may represent a shift in choline metabolism in the AD
brain through enhanced flux in the methionine cycle and transmethylation reactions. Adding
further support to this hypothesis is our observation of overexpression of the choline dehydro-
genase (CHDH) gene in both the ERC and hippocampus in AD. This flavin-dependent mito-
chondrial enzyme oxidizes choline to betaine aldehyde in the methionine cycle [52]. Together
with our recent findings of altered phosphatidylcholine metabolism in AD [9], these results
suggest that enhanced utilization of choline in membrane remodeling by incorporation into
phospholipids, as well as in the transmethylation pathway by its conversion to betaine, may
reduce its availability for the synthesis of acetylcholine within basal forebrain cholinergic neu-
rons. This hypothesis merits further confirmation in experimental studies.
Fig 9. Neurotransmitter metabolism. A lower concentration of GABA is observed in AD in the ITG. The GABA
synthesis genes, SAT1 and MAOB, have increased expression, and the genes GLS2 and OAT have reduced expression
in the hippocampus/ERC in AD compared to CN. Sample size: AD = 17, ASY = 13, CN = 13; p-values indicate
significance after FDR correction for multiple comparisons. An asterisk (�) indicates metabolite was also significant
after Bonferroni correction. Genes in light gray indicate expression data were not available. AD, Alzheimer disease;
ALDH2, aldehyde dehydrogenase 2; ASY, asymptomatic AD; CN, Control; ERC, entorhinal cortex; FDR, false
discovery rate; GAD, glutamate decarboxylase; GDH, glutamate dehydrogenase; GLS2, glutaminase 2; GLUL,
glutamate-ammonia ligase; ITG, inferior temporal gyrus; MAOB, monoamine oxidase B; OAT, ornithine
aminotransferase; P5CDH, delta-1-pyrroline-5-carboxylate dehydrogenase; P5CS, delta-1-pyrroline-5-carboxylate
synthase; SAT1, spermidine/spermine N1-acetyltransferase 1/diamine N-acetyltransferase; TCA, tricarboxylic acid
cycle.
https://doi.org/10.1371/journal.pmed.1003012.g009
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Table 3. Differences in gene expression between AD and CN participants across category-specific genes.
Gene ERC Hippocampus
Log fold-change p-value p-value (FDR) Log fold-change p-value p-value (FDR)
Methionine Cycle
AHCY −0.186 0.044 0.119 −0.435 <0.001 <0.001��
ALDH1L1 −0.147 0.432 0.584 −0.109 0.521 0.651
ALDH1L2 −0.106 0.048 0.126 0.111 0.012 0.040�
AMD1 0.064 0.52 0.661 −0.048 0.623 0.736
BHMT −0.008 0.943 0.967 −0.128 0.241 0.376
BHMT2 0.244 0.012 0.049� 0.155 0.123 0.228
CHDH 0.298 0.002 0.012� 0.286 <0.001 0.005��
DMGDH −0.017 0.791 0.87 −0.065 0.299 0.439
MAT1A 0.351 <0.001 <0.001�� 0.224 <0.001 0.005��
MTHFD1 −0.177 0.049 0.128 −0.225 0.013 0.044�
MTHFD2 0.484 0.111 0.228 −0.042 0.852 0.903
MTHFR 0.046 0.425 0.578 0.116 0.016 0.051
MTR −0.16 0.185 0.327 −0.23 0.01 0.034�
MTRR 0.18 0.119 0.239 −0.002 0.986 0.992
SARDH 0 0.996 0.997 0.066 0.305 0.445
TYMS 0.389 0.041 0.114 0.043 0.819 0.882
SHMT1 0.172 0.052 0.134 0.174 0.007 0.027�
SHMT2 −0.336 <0.001 0.005�� −0.209 0.004 0.019�
Transsulfuration and Glutathione Synthesis
AMT 0.181 0.019 0.067 0.052 0.501 0.635
CTH −0.115 0.174 0.313 −0.402 <0.001 0.001��
DLD −0.491 0.002 0.016� −0.514 <0.001 <0.001��
GCLC −0.205 0.07 0.165 −0.224 0.032 0.083
GCLM 0.037 0.693 0.8 −0.064 0.33 0.472
GLDC 0.152 0.13 0.255 −0.231 0.031 0.08
GSS −0.363 <0.001 <0.001�� −0.349 <0.001 <0.001��
Polyamine Synthesis and Catabolism
PAOX −0.177 0.027 0.086 −0.113 0.147 0.26
SAT1 0.478 <0.001 0.007�� 0.184 0.102 0.198
SAT2 −0.07 0.396 0.551 −0.063 0.374 0.515
SMOX 0.36 <0.001 0.003�� 0.301 <0.001 0.001��
SRM −0.418 <0.001 0.001�� −0.226 0.006 0.024�
Urea Cycle
ARG1 −0.051 0.549 0.685 0.025 0.72 0.81
ARG2 −0.261 0.022 0.073 −0.416 0.002 0.010��
ASL −0.239 0.008 0.036� −0.079 0.316 0.457
ASS1 −0.556 0.002 0.014� −0.233 0.082 0.168
CPS1 0.093 0.256 0.407 0.02 0.803 0.871
GATM 0.936 <0.001 <0.001�� 0.029 0.792 0.862
NAGS 0.132 0.142 0.271 0.187 0.018 0.054
OAT −0.172 0.331 0.488 −0.369 <0.001 0.002��
ODC1 −0.071 0.603 0.729 −0.3 0.014 0.044�
OTC 0.146 0.126 0.249 0.172 0.025 0.07
PYCR1 0.019 0.837 0.898 0.131 0.046 0.109
PYCR2 0.083 0.266 0.418 −0.046 0.509 0.641
(Continued)
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The role of choline in the methionine cycle (Fig 4) is through its oxidation to betaine by
CHDH and the subsequent transfer of a methyl group from betaine to homocysteine to gener-
ate methionine in a reaction catalyzed by betaine-homocysteine methyltransferase (BHMT).
Alternatively, another homocysteine methyltransferase enzyme called 5-methyltetrahydrofo-
late-homocysteine methyltransferase (MTR) uses 5-methyltetrahydrofolate (5-MTHF) as a
methyl donor to convert homocysteine to methionine. The subsequent conversion of methio-
nine to SAM occurs in a two-step reaction catalyzed by methionine adenosyltransferase 1A
(MAT1A). SAM plays a critical role as a universal methyl group donor, participating in more
than 200 enzymatic reactions including phospholipid, DNA, RNA, and protein methylation
[53]. It is therefore striking that we find a significantly higher concentration of SAM in the
Table 3. (Continued)
Gene ERC Hippocampus
Log fold-change p-value p-value (FDR) Log fold-change p-value p-value (FDR)
Glutamate-Aspartate Metabolism
ASNS −0.752 <0.001 <0.001�� −0.722 <0.001 <0.001��
GLS −0.344 0.02 0.068 −0.467 <0.001 <0.001��
GLS2 −0.624 0.003 0.019� −0.904 <0.001 <0.001��
GLUL 0.285 0.059 0.146 −0.007 0.955 0.971
GOT2 −0.713 <0.001 0.001�� −0.444 <0.001 <0.001��
MDH1 −0.888 <0.001 0.009�� −0.929 <0.001 <0.001��
MDH2 −0.596 <0.001 0.004�� −0.673 <0.001 <0.001��
PDC 0.061 0.331 0.487 −0.031 0.539 0.667
Neurotransmitter Metabolism
ALDH1A1 0.537 0.006 0.030� −0.401 0.099 0.194
ALDH2 0.134 0.126 0.248 0.034 0.683 0.782
COMT 0.009 0.919 0.953 0.111 0.05 0.117
DBH −0.133 0.057 0.143 0.133 0.061 0.135
DDC 0.012 0.807 0.88 0.043 0.488 0.623
FAH −0.032 0.804 0.878 −0.089 0.433 0.572
FH −0.197 0.024 0.077 −0.372 <0.001 <0.001��
GSTZ1 0.119 0.159 0.294 0.033 0.732 0.819
HGD 0.055 0.324 0.48 0.11 0.019 0.058
HPD 0.053 0.461 0.61 0.092 0.639 0.748
KYAT1 −0.023 0.705 0.81 0.033 0.612 0.727
KYAT3 −0.72 <0.001 <0.001�� −0.484 <0.001 0.006��
MAOA 0.039 0.723 0.823 0.1 0.336 0.478
MAOB 0.726 <0.001 <0.001�� 0.172 0.16 0.278
ME1 −0.159 0.213 0.36 −0.238 0.01 0.036�
NAT8L −0.069 0.368 0.524 −0.072 0.366 0.508
PAH 0.072 0.687 0.796 0.022 0.87 0.916
PNMT −0.029 0.775 0.858 0.12 0.098 0.193
SLC25A12 −0.431 0.02 0.069 −0.592 <0.001 <0.001��
TAT −0.04 0.5 0.643 −0.026 0.475 0.611
TH −0.2 0.284 0.439 −0.279 0.088 0.178
�Indicates FDR-corrected p-value<0.05.
��Indicates FDR-corrected p-value<0.01.
Abbreviations: AD, Alzheimer disease; CN, control; ERC, entorhinal cortex; FDR, false discovery rate
https://doi.org/10.1371/journal.pmed.1003012.t003
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ITG in AD compared to controls; higher SAM concentration was also associated with more
severe neuritic plaque and neurofibrillary tangle pathology. Consistent with our results, Paglia
and colleageus observed an increase in SAM concentrations in the frontal cortex in AD [46].
However, in contrast to these results, a previous postmortem study in humans found
decreased SAM in all cortical regions examined compared to controls [4]. Both methodologi-
cal differences in measuring SAM concentrations as well as differences in the participant’s age
(75–76 years versus 86 years) and duration of disease may account for this inconsistency.
Our transcriptomic analysis in the hippocampus and ERC provides complementary evi-
dence for alterations in the genetic regulators of enzymatic reactions of the methionine cycle
in AD. Besides altered gene expression of CHDH, we found differential gene expression of the
two homocysteine methyltransferase enzymes, BHMT2 and MTR, that catalyze the conversion
of homocysteine to methionine. We also observed lower expression of the MTHFD1 gene that
encodes a trifunctional C1-tetrahydrofolate (THF) synthetase catalyzing the ATP-dependent
conversion of THF and formate to 5,10-MethyleneTHF (CH2THF). The irreversible reduction
of CH2THF by the enzyme 5,10-methylene THF reductase (MTHFR) generates 5-methylTHF,
a key methyl donor for the remethylation of homocysteine to methionine [54]. These findings
add to emerging evidence for methionine metabolism as an important modulator of neurode-
generation as well as a metabolic determinant of longevity in several animal models [55–57].
Fig 10. Differential gene expression within ERC and hippocampus. Summary of genes differentially expressed in the
hippocampus/ERC in AD compared to controls across all six categories of biochemical reactions related to transmethylation and
polyamine metabolism. Gray shading indicates gene expression was not significantly different between AD and control. AD,
Alzheimer disease; CN, Control; ERC, entorhinal cortex.
https://doi.org/10.1371/journal.pmed.1003012.g010
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Intriguingly, recent genome-wide association studies (GWAS) have implicated polymorphic
variations in MAT1A as being associated with both longevity and cognitive performance dur-
ing aging [58]. Our findings are also consistent with a previous study implicating elevated
plasma homocysteine levels as risk factors for both cerebrovascular disease and AD [54,59].
Strikingly, we also found overexpression of serine hydroxymethyltransferase 1 (SHMT1) in
the hippocampus in AD. SHMT1 is a pyridoxal phosphate-containing enzyme that catalyzes
the reversible conversion of serine and THF to glycine and CH2THF. Besides its role as a
methyl group donor for the remethylation of homocysteine, CH2THF is also a source of
methyl groups for the synthesis of thymidylate or deoxythimidine monophosphate (dTMP)
from deoxyuridine monophosphate (dUMP). The net effect of reduced CH2THF may be
impaired de novo dTMP synthesis and a greater rate of uracil misincorporation into DNA,
resulting in single- and double-stranded breaks through the actions of DNA repair enzymes
[60]. Our findings assume importance given previous studies implicating genome instability
and impaired DNA repair in AD pathogenesis [61].
Transsulfuration and glutathione synthesis (Fig 5)
Besides its role in the methionine cycle as a substrate for conversion to methionine, an alterna-
tive metabolic fate of homocysteine is in the transsulfuration pathway (Fig 5), where it can be
used to generate cysteine, a precursor of the principal antioxidant tripeptide, glutathione. Our
metabolomics analyses revealed significantly higher concentrations of both cysteine and thiol-
reduced glutathione (GSH) in the ITG in AD as well as associations with both metabolites and
more severe amyloid and neurofibrillary pathology. These results suggest that AD is character-
ized by a state of increased oxidative stress with a greater demand for recruitment of antioxi-
dant defense mechanisms through GSH. Additionally, besides its well-established role as a free
radical scavenger, GSH is also involved in detoxification of electrophiles and plays numerous
roles in diverse cellular functions of relevance to neurodegeneration, including DNA synthesis,
posttranslational modification of proteins and immune function [62,63]. Our results suggest
that higher levels of cysteine, the rate-limiting substrate for GSH synthesis, are indicative of a
greater drive towards generation of GSH in brain regions vulnerable to AD pathology. These
findings are consistent with a previous postmortem metabolomics analysis in humans by Xu
and colleagues that showed significantly higher levels of cysteine in the hippocampus and cin-
gulate gyrus in AD [1]. Previous MRS studies have shown inconsistent findings with reports of
decreased GSH levels in the frontal cortex and hippocampus in AD, whereas MCI individuals
appear to have increased GSH levels in the anterior and posterior cingulate cortices. The latter
report by Duffy and colleagues is especially relevant in the context of our current findings, as
the authors hypothesize that higher GSH levels in early stages of AD progression may be a
compensatory mechanism to counter cysteine-induced excitotoxicity through activation of N-
methyl-D-aspartate (NMDA) receptors [64].
Consistent with our metabolomics results, we found altered expression of genes encoding
enzymes catalyzing reactions essential for GSH synthesis in the hippocampus/ERC in AD.
These include significantly reduced expression of cystathionine gamma-lyase (CTH), which
breaks down cystathionine into cysteine, the rate-limiting substrate for glutathione synthesis
as well as GSH synthase (GSS), catalyzing the second step in GSH synthesis.
Polyamine synthesis and catabolism (Fig 6)
We observed a significantly higher concentration of spermidine in the ITG in AD, as well as
associations with more severe amyloid pathology and neurofibrillary pathology. Our results
are broadly consistent with other studies on human postmortem samples comparing AD and
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control brains as well as a mouse model of AD showing increased brain polyamine concentra-
tions [2,3,65]. Ornithine decarboxylase 1 (ODC1) is the first rate-limiting enzyme in poly-
amine biosynthesis (Fig 6) and catalyzes the conversion of ornithine, generated in the urea
cycle (discussed below) to putrescine. The generation of SAM in the methionine cycle
(described above) is involved in the second rate-limiting step of spermidine and spermine bio-
synthesis through its decarboxylation by the enzyme SAM decarboxylase (AMD1) [66]. This
reaction generates decarboxylated SAM that is a source of aminopropyl groups, which are suc-
cessively added to putrescine to generate spermidine and spermine in reactions catalyzed by
spermidine synthase (SRM) and spermine synthase (SMS), respectively. Taken together with
our observation of increased SAM concentration in AD, higher concentrations of spermidine
may suggest enhanced drive towards greater polyamine biosynthesis in AD. Altered brain
polyamine metabolism may impact AD progression through several mechanisms, including
modulation of cholinergic neurotransmission and activity of NMDA receptors [67]. While
high polyamine concentrations have been shown to reduce neuronal survival, they provide
trophic support during synaptogenesis in the developing brain and are therefore likely to play
complex, pleiotropic roles in AD progression [68–70].
Our transcriptomic analysis suggests differential regulation of both polyamine biosynthesis
and catabolism in AD with reduced expression of SRM and ODC1 and increased expression
of the catabolic enzymes spermine oxidase (SMOX) and spermine/spermidineN1-acetyltrans-
ferase (SAT1). ODC1 encodes ornithine decarboxylase, the rate-limiting enzyme in the bio-
synthesis of polyamines, while SAT1 is the rate-limiting enzyme of polyamine catabolism and
catalyzes the acetylation of spermine and spermidine, which can then be oxidized by poly-
amine oxidase (PAOX). The role of SAT1 in mental illness has been particularly well studied
in major depression and suicide and is one of the most consistently implicated genes in these
conditions [71,72]. The degradation of polyamines by SMOX and PAOX results in the genera-
tion of hydrogen peroxide and the neurotoxic aldehyde 3-aminopropanal (3-AP) [73,74].
Reactive aldehyde species such as 3-AP have been extensively studied as cytotoxic metabolites
in neurodegeneration as well as cerebral ischemia [75]. Together, our findings suggest both
direct cytotoxic effects from increased polyamine synthesis as well as from reactive aldehydes
generated through enhanced polyamine catabolism in AD.
Urea cycle (Fig 7)
We observed lower concentrations of N-acetyl glutamate (NAG) in the ITG in AD, as well as
associations with lower NAG concentrations and more severe amyloid and neurofibrillary
pathology. These results are similar to those reported by Xu et al. who observed lower NAG
levels in the ERC in AD using GC-MS. However, in contrast to prior reports by Xu et al. and
Liu et al. using LC-MS, we did not find lower brain concentration of ornithine in AD [1,2].
Abnormalities in the urea cycle and their potential role in AD have received attention after
microarray experiments showed altered expression of the urea cycles enzymes in the AD brain
[76]. The primary regulated step in the urea cycle is the reaction catalyzed by the mitochon-
drial enzyme, carbamoyl phosphate synthetase 1 (CPS1), that synthesizes carbamoyl phosphate
from inorganic ammonium and carbonate (Fig 7). CPS1 requires NAG as an essential cofactor,
which is synthesized in a reaction catalyzed by another mitochondrial enzyme, N-acetylgluta-
mate synthase (NAGS) from glutamate and acetyl CoA. We observed differences in gene
expression of key regulators of the urea cycle; in particular, the mitochondrial enzymes ASS1,
OAT, ARG2, ODC1, and the cytosolic enzyme ASL showed reduced expression in the ERC/
hippocampus in AD. ASS1 catalyzes the conversion of citrulline to argininosuccinate, the rate-
limiting step in arginine synthesis, and together with ASL, recycles citrulline into arginine in
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the urea cycle. OAT catalyzes the conversion of ornithine into the major excitatory and inhibi-
tory neurotransmitters glutamate and GABA, respectively [77]. In agreement with previous
studies that showed altered brain arginase activity in AD [2], we found reduced expression of
ARG2. Previous gene expression analyses have reported both increased and reduced expres-
sion of ARG2 in the AD brain [76,78]. Taken together, our findings add further evidence
implicating dysregulation of the urea cycle as a key metabolic abnormality in AD that can also
impact other biochemical pathways including polyamine metabolism (as discussed above) as
well as neurotransmitter metabolism (discussed below).
Glutamate-aspartate metabolism (Fig 8)
Consistent with numerous prior studies using 1H-MRS that have shown lower levels of NAA
in AD within regions vulnerable to pathology, such as the posterior cingulate cortex and hip-
pocampus [51], our CE-MS assays also showed evidence of lower NAA concentration in the
ITG in AD as well as associations with lower concentrations and more severe amyloid pathol-
ogy and neurofibrillary pathology. Besides being a well-recognized neuroimaging marker of
neuronal metabolic integrity, NAA plays several important biological roles including in myelin
turnover, mitochondrial energy production, neuronal osmoregulation, and neuron-glia signal-
ing [79–81]. Its synthesis within neurons occurs in an energy-dependent reaction that is cata-
lyzed by neuron-specific N-acetyltransferase (NAT8L) (Fig 8), utilizing glutamate as a
transamination source for aspartate and either pyruvate or 3-hydroxybutyrate as a source of
acetyl CoA [80]. While lower NAA levels in neurodegenerative diseases may be a marker of
neuronal loss, they may also reflect compromised NAA synthesis within neurons facing
increasing bioenergetic demand due to perturbations in mitochondrial oxidative phosphoryla-
tion. In this context, it is interesting to note that Zaroff and colleagues recently reported
under-expression of NAT8L as well as NAA levels in a transgenic mouse model of AD, even in
the absence of significant neuronal loss [81]. Our findings are in broad agreement with those
of Paglia and colleagues who showed evidence for dysregulation in brain aspartate and gluta-
mate metabolism in AD [46]. There are significant methodological differences between this
prior report and our current study, in that Paglia and colleagues used an untargeted metabolo-
mics approach. This may explain some inconsistencies between our current results and their
findings, including their observation of increased NAA levels in AD.
Our transcriptomic results add further support to evidence that mitochondrial energy pro-
duction is a key abnormality in AD. We observed significantly reduced expression of the gluta-
mate oxaloacetate transaminase (GOT2) gene in both the ERC and hippocampus in AD.
GOT2 catalyzes a key mitochondrial transamination reaction that allows rapid generation of
ATP by bypassing initial steps in the TCA cycle. This reaction is essential to the “mini citric
acid cycle” described by Yudkoff and colleagues and allows rapid energy generation required
for neuronal activity [82]. Moreover, aspartate generated in this reaction can serve as a sub-
strate for NAA production. Therefore, our findings of lower NAA concentration and reduced
expression of GOT2 further implicate impaired mitochondrial energy production in AD
pathogenesis.
Neurotransmitter metabolism (Fig 9)
Our observation of lower GABA concentration in both the ITG and MFG in AD is consistent
with prior studies in postmortem brain tissue samples [51,83–85]. Additionally, we found that
lower GABA concentration across all three brain regions was associated with more severe
amyloid pathology and neurofibrillary pathology. This suggests that impaired GABA neuro-
transmission may be a regionally widespread phenomenon that may impact severity of AD
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pathology. These findings are especially relevant, as impaired balance between excitatory and
inhibitory neurotransmission is emerging as an important mediator of clinical progression in
AD, and modulation of GABA signaling may be a novel therapeutic strategy for disease modi-
fication [86]. Our gene expression analyses also revealed overexpression of MAO-B, a gene
regulating neurotransmitter catabolism, in the ERC. While these results are consistent with
early autoradiographic studies that revealed significantly higher MAO-B activity in the AD
brain [87], increased MAO-B uptake detected by positron emission tomography (PET) is
emerging as a promising biomarker of neuroinflammation and reactive astrocytosis in early
stages of AD [88]. A direct role for MAO-B in AD is also suggested by recent findings that that
MAO-B is a γ-secretase–associated protein capable of regulating intraneuronal Aβ levels [89].
MAO-B also catalyzes the second of four sequential reactions in the synthesis of GABA from
putrescine, by converting N-acetylputrescine to N-acetyl-γ-aminobutyraldehyde. This reaction
is known to occur predominantly within astrocytes [90,91]. Thus, our results suggest that the
up-regulation of MAO-B may be a compensatory mechanism against presumably lower
GABA biosynthesis within neuronal cells [92].
Fig 11 summarizes our overall findings by integrating metabolite and gene expression
results across all six categories of biochemical reactions we examined and clearly shows how
these pathways intersect and potentially interact at numerous levels to influence severity of AD
pathology and symptom expression.
Conclusions and limitations
To the best of our knowledge, this is the first study to apply targeted metabolomics using
CE-MS in brain tissue samples in combination with analyses of gene expression to identify
abnormalities in multiple metabolic networks related to the transmethylation and polyamine
pathways in AD. Some limitations of our study merit consideration. Our CE-MS–based meta-
bolomics assays detected only a small proportion of all metabolites participating in the path-
ways we examined. Our interpretation of the results is therefore limited to analytes that could
be reliably detected. The analyses of gene expression were performed on previously published
and publicly available datasets distinct from the BLSA. We overlaid gene expression results
from these datasets on our metabolomics analyses to enhance interpretability of our findings
and derive plausible biological mechanisms underlying changes in brain metabolite levels in
AD. Furthermore, we focused on gene expression profiles in the ERC and hippocampus,
whereas our metabolomics assays were performed in the ITG, MFG, and CB. However, we
confirmed that gene expression changes in the ITG were correlated with those in the ERC and
hippocampus. Our rationale to focus on the ERC and hippocampus was that accumulation of
pathology in these regions is thought to trigger onset of cognitive impairment in AD [27–29].
The limited availability of tissue samples from the ERC and hippocampus precluded metabolo-
mics assays on these two regions in our study. Another limitation was the cross-sectional
nature of our metabolomic and transcriptomic analyses. We were therefore unable to directly
assess how AD progression may impact changes in brain tissue concentrations of metabolites
or up- or down-regulation of genes within specific pathways. This study design also makes any
definitive conclusions about directionality of metabolite and gene expression changes chal-
lenging. Thus, we are unable to assess whether up- or down-regulation of gene expression lead
to changes in metabolite concentrations or represent adaptive responses to alterations in
metabolite levels. However, integrating metabolomics and transcriptomics analyses to map a
priori–specified biochemical pathways may provide important insights into how AD may
broadly impact multiple interlinked metabolic pathways. An additional limitation is that our
brain tissue and gene expression sample size was small, and we explored associations across
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multiple metabolites and genes within a limited sample. We were therefore likely underpow-
ered to detect all alterations in the pathway-specific metabolites and genes that we studied.
Additionally, studies with small sample sizes may be underpowered to extrapolate results to a
larger population [96], and significant results may not reflect true effects [97]. Considering
these sample size limitations, we specified a priori hypotheses with metabolites of interest and
implemented FDR and Bonferroni adjustments to control for multiple comparisons to reduce
potential biases. Finally, it is also worth considering that in an autopsy-based assessment of a
neurodegenerative disease such as AD, some observed changes may be nonspecific markers of
terminal events related to neuronal loss. The specificity of our findings merit testing in other
neurodegenerative diseases in future studies.
Our results implicate alterations in cellular methylation potential and increased flux in
the transmethylation pathways, increased demand on antioxidant defense mechanisms, per-
turbations in intermediate metabolism in the urea cycle and aspartate-glutamate pathways
Fig 11. Integrated summary of alterations in metabolite concentrations and gene expression within metabolic pathways linked
to transmethylation and polyamine synthesis/catabolism. Reactions within each of the six categories related to transmethylation
and polyamine metabolism are shown within brown boxes [93–95]. Metabolites whose concentrations are increased in the AD
ITG relative to controls are shown in red boxes; those that are reduced in AD are shown in green boxes. Metabolites whose
concentrations were measured but did not differ between AD and control are indicated in blue boxes; metabolites whose
concentrations were not assayed are shown in gray boxes. Red up and green down arrows indicate significantly increased and
reduced gene expression in the ERC/hippocampus, respectively. AD, Alzheimer disease; AHCY, adenosylhomocysteinase; ALDH2,
aldehyde dehydrogenase 2; AMD1, adenosylmethionine decarboxylase 1; AMT, aminomethyltransferase; ARG2, arginase 2; ASL,
argininosuccinate lyase; ASNS, asparagine synthetase; ASS1, argininosuccinate synthase 1; BHMT2, betaine homocysteine s-
methyltransferase 2; CBS, cystathionine beta synthase; CN, Control; COMT, catechol-o-methyltransferase; CPS1, carbamoyl
phosphate synthase 1; CTH, cystathionine gamma-lyase; DLD, dihydrolipoamide dehydrogenase; ERC, entorhinal cortex; GAD1,
glutamate decarboxylase 1; GATM, glycine amidino transferase; GCLC, glutamate cysteine ligase catalytic; GCLM, glutamate
cysteine ligase modifier; GCSH, glycine cleavage system protein H; GLDC, glycine decarboxylase; GLS2, glutaminase 2; GLUL,
glutamine synthetase; GOT2, glutamic oxaloacetic transaminase 2; GSS, GSH synthetase; HC, hippocampus; ITG, inferior temporal
gyrus; KYAT3, kynurenine aminotransferase 3; MAT1A, methionine adenosyltransferase 1A; MFG, middle frontal gyrus; MOAB,
monoamine oxidase B; MTHFD2, methylenetetrahydrofolate dehydrogenase 2; MTHFR, methylenetetrahydrofolate reductase;
MTR, methyltransferase; NAT8L, n-acetyltransferase 8 like; OAT, ornithine aminotransferase; ODC1, ornithine decarboxylase 1;
OTC, ornithine carbamoyltransferase; PAOX, polyamine oxidase; SAT1, spermidine/spermine n1-acetyltransferase 1; SHMT1,
serine hydroxymethyl transferase 1; SMOX, spermine oxidase; SMS, spermine synthase; SRM, spermidine synthase.
https://doi.org/10.1371/journal.pmed.1003012.g011
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disrupting mitochondrial bioenergetics, increased polyamine biosynthesis and breakdown, as
well as abnormalities in neurotransmitter metabolism that are related to severity of AD pathol-
ogy and the expression of clinical symptoms. They illustrate the contours of AD as a pervasive
metabolic disorder that may involve dysregulation of multiple interconnected metabolic path-
ways that are each capable of triggering accumulation of AD pathology and eventual evolution
of symptoms. We believe that this study significantly adds to a comprehensive understanding
of the metabolic basis of AD pathogenesis and provides insights into novel targets for disease-
modifying therapies.
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